Skip to content
value.today

Cellanome, Inc.

Total raised
$269 M
4 rounds on record
Latest round
$76 M
Dec 2025
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cellanome, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$76 MNo. 4$50 to $250 million

Cellanome, Inc.: Raise no. 4, Dec 2025

Investors in this round

22 investors had bought by the notice of Jun 22, 2026: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$76 M of $76 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mehdi Khodadad · Executive Officer · Secretary
  • Omead Ostadan · Executive Officer, Director
  • Jay Flatley · Director
  • Mostafa Ronaghi · Director
  • Rowan Chapman · Director
  • Sandesh Patnam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Omead Ostadan, Chief Executive Officer and President of the Issuer. Source: SEC Form D, newest notice filed Jun 22, 2026. Read the notice at the SEC.

equitySEC
Dec 2023$150 MNo. 3$50 to $250 million

Cellanome, Inc.: Raise no. 3, Dec 2023

Investors in this round

20 investors had bought by the notice of Jan 29, 2024: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
$60,002
What was sold
equity, other: Series B Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ali Agah · Executive Officer
  • Mehdi Khodadad · Executive Officer
  • Omead Ostadan · Executive Officer, Director, Promoter
  • Sue McGrath · Executive Officer
  • Tarun Khurana · Executive Officer
  • Jay Flatley · Director
  • Mostafa Ronaghi · Director
  • Rowan Chapman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Omead Ostadan, Chief Executive Officer and President of the Issuer. Source: SEC Form D, newest notice filed Jan 29, 2024. Read the notice at the SEC.

equitySEC
Jul 2022$41 MNo. 2$10 to $50 million

Cellanome, Inc.: Raise no. 2, Jul 2022

Investors in this round

11 investors had bought by the notice of Mar 21, 2023: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$41 M of $41 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A-2 Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kazutaka Ohno · Executive Officer
  • Omead Ostadan · Executive Officer, Director, Promoter
  • Jay Flatley · Director
  • Mostafa Ronaghi · Director
  • Rowan Chapman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Omead Ostadan, Chief Executive Officer and President of the Issuer. Source: SEC Form D and 1 amendment, newest notice filed Mar 21, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$2 MNo. 1$2 to $10 million

Cellanome, Inc.: Raise no. 1, Sep 2021

Investors in this round

17 investors had bought by the notice of Oct 5, 2021: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ali Agah · Executive Officer, Director
  • Kazutaka Kumar Ohno · Executive Officer
  • Tarun Kumar Khurana · Executive Officer, Director
  • Mostafa Kumar Ronaghi · Director
  • Omead Kumar Ostadan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ali Agah, Chief Executive Officer and President of the Issuer. Source: SEC Form D, newest notice filed Oct 5, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cellanome, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

That is all the official record says: Cellanome, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cellanome, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cellanome, Inc.
NameRoleNamed in
Mehdi KhodadadSecretaryJun 2026
Omead OstadanExecutive officerJun 2026
Ali AgahExecutive officerJan 2024
Sue McGrathExecutive officerJan 2024
Tarun KhuranaExecutive officerJan 2024
Kazutaka OhnoExecutive officerMar 2023
Kazutaka Kumar OhnoExecutive officerOct 2021
Tarun Kumar KhuranaExecutive officerOct 2021
Jay FlatleyDirectorJun 2026
Mostafa RonaghiDirectorJun 2026
Omead OstadanDirectorJun 2026
Rowan ChapmanDirectorJun 2026
Sandesh PatnamDirectorJun 2026
Ali AgahDirectorAug 2022
Mostafa Kumar RonaghiDirectorOct 2021
Omead Kumar OstadanDirectorOct 2021
Tarun Kumar KhuranaDirectorOct 2021
Omead OstadanPromoterJan 2024